4BIO Capital
4BIO Capital is a London-based venture capital firm dedicated to the advanced therapies sector. The firm invests in early-stage life sciences companies that are developing treatments for significant medical and social needs. Its investment focus includes areas such as cell therapy, gene therapy, RNA-based therapy, targeted therapies, and microbiome-based treatments. The firm aims to support and grow early-stage companies, helping to translate scientific innovation into potentially curative therapies for patients. 4BIO Capital is comprised of a team of academics, physician-scientists, industry
Investing activity
4BIO Capital appears in 1 AI deal tracked by the Lounge deals desk, rounds totalling $18M, and led 1 of them. The rounds are mostly Seed, with a median round size of $18M. The most recent is Undecimal Bio (Seed, $18M, Oct 2026).
4BIO Capital most often invests alongside IQ Capital, Entrée Capital, Kerna Ventures and Verve Ventures, and the companies it backs on Lounge are mostly in AI.
Deals
Frequently asked questions about 4BIO Capital
What AI companies has 4BIO Capital invested in?
4BIO Capital's AI investments include Undecimal Bio. The 1 round on Lounge are listed on this page with amounts, dates and co-investors.
Where is 4BIO Capital based?
4BIO Capital is based in London, England, United Kingdom.
What stage does 4BIO Capital invest at?
In the rounds tracked on Lounge, 4BIO Capital has invested at Seed, with a median round of $18M. 4BIO Capital led 1 of those rounds.
Who does 4BIO Capital co-invest with?
4BIO Capital's most frequent co-investors on Lounge are IQ Capital (1 deal), Entrée Capital (1 deal), Kerna Ventures (1 deal), Verve Ventures (1 deal) and Harel Insurance and Financial (1 deal).
How can founders reach 4BIO Capital?
Founders on Lounge can see 4BIO Capital's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add 4BIO Capital to their Investor Pipeline to track the conversation.